Breaking from the paradigm of antibody-drug conjugates: Evaluation of clinical pharmacokinetics and safety of bicycle toxin conjugates (BTCs)

被引：0
|
作者：
Bader, Justin
McKean, Meredith
DeMars, Leslie Robbins
Lu, Yasong
Li, Mengyao
Dickson, Amy
Bennett, Gavin
Arroyo, Santiago
Fontana, Elisa
Carter, Louise
Ahnert, Jordi Rodon
Falchook, Gerald Steven
Xu, Hongmei
机构：
[1] Bicycle Therapeut, Cambridge, MA USA
[2] Sarah Cannon Res Inst, Nashville, TN USA
[3] BicycleTx Ltd, Cambridge, England
[4] Sarah Cannon Res Inst UK, London, England
[5] Univ Manchester, Manchester, England
[6] Christie NHS Fdn Trust, Manchester, England
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[8] HealthONE, Sarah Cannon Res Inst, Denver, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3088
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates
    Nieto-Jimenez, Cristina
    Sanvicente, Adrian
    Diaz-Tejeiro, Cristina
    Moreno, Victor
    Lopez de Sa, Alfonso
    Calvo, Emiliano
    Martinez-Lopez, Joaquin
    Perez-Segura, Pedro
    Ocana, Alberto
    CLINICAL AND TRANSLATIONAL MEDICINE, 2023, 13 (09):
  • [32] Clinical strategies with antibody-drug conjugates as potential modifications for virotherapy
    Liao, Zi-Xian
    Huang, Po-Hsiang
    Hsu, Shan-hui
    Chang, Hsiung-Hao
    Chang, Chi-Heng
    Tseng, S. -Ja
    DRUG DISCOVERY TODAY, 2024, 29 (11)
  • [33] Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies
    He, Jun
    Zeng, Xianghua
    Wang, Chunmei
    Wang, Enwen
    Li, Yongsheng
    MEDCOMM, 2024, 5 (08):
  • [34] Current Trends in the Clinical Development of Antibody-Drug Conjugates in Oncology
    Dott J.
    Abila B.
    Wuerthner J.U.
    Pharmaceutical Medicine, 2018, 32 (4) : 259 - 273
  • [35] Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates
    Sapra, Puja
    Betts, Alison
    Boni, Joseph
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2013, 6 (05) : 541 - 555
  • [36] Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
    Dan, Nirnoy
    Setua, Saini
    Kashyap, Vivek K.
    Khan, Sheema
    Jaggi, Meena
    Yallapu, Murali M.
    Chauhan, Subhash C.
    PHARMACEUTICALS, 2018, 11 (02)
  • [37] Synthesis and evaluation of homocamptothecin antibody-drug conjugates for cancer treatment
    Li, Yalong
    Cheng, Zhiyang
    Zhou, Wei
    Wang, Lei
    Li, Xiaomei
    Xia, Guangxin
    Lu, Wei
    Zhu, Shulei
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 279
  • [38] Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates
    Kolodych, Sergii
    Michel, Chloe
    Delacroix, Sebastien
    Koniev, Oleksandr
    Ehkirch, Anthony
    Eberova, Jitka
    Cianferani, Sarah
    Renoux, Brigitte
    Krezel, Wojciech
    Poinot, Pauline
    Muller, Christian D.
    Papot, Sebastien
    Wagner, Alain
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 142 : 376 - 382
  • [39] Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development
    Kwon, Whi-An
    Lee, Seo-Yeon
    Jeong, Tae Yoong
    Kim, Hyeon Hoe
    Lee, Min-Kyung
    CANCERS, 2024, 16 (13)
  • [40] Antibody-drug conjugates in gastric cancer: from molecular landscape to clinical strategies
    Hao, Jia-Lin
    Li, Xin-Yun
    Liu, Yu-Tong
    Lang, Ji-Xuan
    Liu, Di-Jie
    Zhang, Chun-Dong
    GASTRIC CANCER, 2024, 27 (05) : 887 - 906
12345